When treating Alzheimer’s, earlier is better, according to analysis of Lilly and Eisai trials

The drug­mak­ers be­hind the new class of Alzheimer’s treat­ments are co­a­lesc­ing around a com­mon nar­ra­tive: when it comes to slow­ing the dis­ease, the ear­li­er a pa­tient is treat­ed, the bet­ter.

In Boston Wednes­day, Ei­sai and Eli Lil­ly each took to the stage of the sold-out Clin­i­cal Tri­als on Alzheimer’s Dis­ease con­fer­ence with cuts of da­ta from their large piv­otal stud­ies look­ing at how sub­sets of pa­tients in the tri­al re­spond­ed to treat­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.